Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms
Mirabegron has been registered as the first strong and selective agonist of the β3 receptor. It is currently used for relief of symptoms of overactive bladder (OAB). That onerous illness involving urgency and detrusor overactivity, that may be accompanied by incontinence, affects approx. 16% of the...
Main Authors: | Tomasz Aleksiewicz, Kamil Leis, Wojciech Świerczyński, Kacper Miętkiewicz, Katarzyna Litwin, Przemysław Gałązka |
---|---|
Format: | Article |
Language: | English |
Published: |
Kazimierz Wielki University
2018-08-01
|
Series: | Journal of Education, Health and Sport |
Subjects: | |
Online Access: | http://www.ojs.ukw.edu.pl/index.php/johs/article/view/5864 |
Similar Items
-
Mirabegron: A first-in-class beta-3 agonist for overactive bladder
by: Suruchi Aditya, et al.
Published: (2015-01-01) -
The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
by: Marilena Gubbiotti, et al.
Published: (2019-01-01) -
Profile of mirabegron in the treatment of overactive bladder: place in therapy
by: Sharaf A, et al.
Published: (2017-02-01) -
Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
by: Se Yun Kwon, et al.
Published: (2020-07-01) -
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
by: Jameel Nazir, et al.
Published: (2018-09-01)